• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » J&J’s medical device sales take a hit

J&J’s medical device sales take a hit

January 20, 2015 By Brad Perriello

J&J's medical device sales take a hit

Johnson & Johnson‘s (NYSE:JNJ) medical device business posted top-line slides for both the 4th quarter and 2014, even excluding the effects of the strong dollar that helped to push down sales for the healthcare giant.

New Brunswick, N.J.-based J&J reported worldwide medical device sales of $6.65 billion for the 4th quarter, a 9% decline compared with the same period in 2013 and a 4.7% slide on a constant-currency basis. The division brought in full-year revenues of $27.52 billion, down 3.4% compared with the prior year and off 1.6% excluding currency effects.

"2014 was a strong year for Johnson & Johnson, as we delivered solid financial results while continuing to make investments to accelerate growth for the long term. We have built significant momentum in our pharmaceutical business, are realizing the benefits of innovation, scale and breadth in our medical devices business and are continuing our market leadership with iconic brands in our consumer business," chairman & CEO Alex Gorsky said in prepared remarks. "I am proud of our exceptional Johnson & Johnson colleagues who make our success possible with their commitment to advancing health and well-being for patients and consumers around the world."

Overall 4th-quarter profits fell about 28% to $2.52 billion, or 89¢ per share, including a $1.1 billion charge related to Johnson & Johnson’s $21.3 billion buyout of Synthes in 2012. Excluding 1-time items, J&J earned $1.27 per share, a penny above expectations on Wall Street. Total sales fell 0.6% to $18.25 billion for the quarter.

J&J forecast adjusted earnings of $6.12 to $6.27 per share for 2015, but said that it changed its definition of adjusted earnings to include after-tax amortization and special items. Include those, which J&J put at about 32¢, and the guidance becomes $5.80 to $5.95 per share, well below the The Street’s $6.16 consensus estimate.

Q4 sales were off -0.6% for J&J’s orthopedics business but up 2.8% on a constant-currency basis. U.S. orthopedics sales grew 2.4% and international sales slipped -4.1% (+3.3% CC).

JNJ shares were trading at $101.09 apiece in early-morning activity, down 2.8%.

Material from Reuters was used in this report.

Filed Under: MassDevice Earnings Roundup, News Well, Orthopedics Tagged With: 2014, Johnson and Johnson, Q4

More recent news

  • Neuralink files to raise $649M in new equity offering
  • BofA: surgical robot remanufacturing not a major setback for Intuitive
  • InspireMD wins CE Mark approval for CGuard Prime
  • Philips reports first cases for VeriSight Pro 3D ICE catheter in Europe
  • Ceryx Medical raises $15M to support bioelectronic pacemaker

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy